This article has been cited by other articles in PMC.
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (654K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
These references are in PubMed. This may not be the complete list of references from this article.
Pacifici GM, Nardini M, Ferrari P, Latini R, Fieschi C, Morselli PL. Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect. Br J Clin Pharmacol. 1976 Oct;3(5):883–889.[PubMed]
Bleidner WE, Harmon JB, Hewes WE, Lynes TE, Hermann EC. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965 Dec;150(3):484–490.[PubMed]
Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL. Amantadine toxicity in a patient with renal insufficiency. Nephron. 1974;13(2):183–186.[PubMed]
Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc. 1975 May;23(5):212–215.[PubMed]
Vernier VG, Harmon JB, Stump JM, Lynes TE, Marvel JP, Smith DH. The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol Appl Pharmacol. 1969 Nov;15(3):642–665.[PubMed]
Weinstein L, Chang TW. The chemotherapy of viral infections. N Engl J Med. 1973 Oct 4;289(14):725–730.[PubMed]
Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association